Defibrotide therapy for SARS-CoV-2 ARDS
Background SARS-CoV-2-related ARDS is associated with endothelial dysfunction and
profound dysregulation of the thrombotic-fibrinolytic pathway. Defibrotide is a polyanionic
compound with fibrinolytic, antithrombotic, and antiinflammatory properties. Research
Question What is the safety and tolerability of defibrotide in patients with severe SARS-CoV-
2 infections? Study Design and Methods We report a prospective, open-label, single-center
safety trial of defibrotide for the management of SARS-CoV-2-related ARDS. Eligible …
profound dysregulation of the thrombotic-fibrinolytic pathway. Defibrotide is a polyanionic
compound with fibrinolytic, antithrombotic, and antiinflammatory properties. Research
Question What is the safety and tolerability of defibrotide in patients with severe SARS-CoV-
2 infections? Study Design and Methods We report a prospective, open-label, single-center
safety trial of defibrotide for the management of SARS-CoV-2-related ARDS. Eligible …